The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

This amounts to one of the most significant federal government investments in the behavioral health sector in history. For ...

Asian American populations, particularly when broken down into ethnic groups, have allergy health outcomes that are distinct ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.

Basic public health protections help augment our national security protections,” particularly when it comes to emerging ...

Enrollment of Black and Hispanic students in medical schools dropped precipitously last year after the Supreme Court banned ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...